文献速递类风湿关节炎

真实世界类风湿关节炎队列中TNFi与非TNFi生物制剂因疗效不佳/失效及不良事件停药率相似

Discontinuation of biologic therapy due to lack/loss of response and adverse events is similar between TNFi and non-TNFi class: Results from a real-world rheumatoid arthritis cohort.
PubMed 文献 · Semin Arthritis Rheum · 2020-07-14

该观察性队列研究纳入OBRI中2010年后启动生物制剂的932例类风湿关节炎患者,其中非TNFi组174例、TNFi组758例。中位随访1.7年,经倾向评分校正后,两组因任何原因、疗效不佳/失效及不良事件停药的风险均无显著差异,提示这些原因不应驱动TNFi与非TNFi的选择。

要点

  • 两组因任何原因停药风险无显著差异(HR 1.14,95%CI 0.90-1.46,p=0.28)。
  • 因疗效不佳/失效停药风险无显著差异(HR 1.01,95%CI 0.70-1.47,p=0.95)。
  • 因不良事件停药风险无显著差异(HR 1.06,95%CI 0.64-1.73,p=0.83)。

核心结论

  • 在真实世界类风湿关节炎队列中,启动TNFi与非TNFi生物制剂的患者停药情况相似。
  • 因疗效不佳/失效或不良事件停药在两类生物制剂间无显著差异,提示这些原因不应作为选择TNFi或非TNFi的依据。

研究设计与样本

  • 观察性队列研究,纳入Ontario Best Practices Research Initiative(OBRI)中2010年1月1日及以后启动生物制剂的类风湿关节炎患者。
  • 共纳入932例患者,非TNFi组174例(18.7%),TNFi组758例(81.3%)。
  • 采用Kaplan-Meier生存分析和Cox比例风险回归分析评估停药时间,并校正倾向评分。

主要发现

  • 中位随访1.7年,416例(44.6%)因任何原因停药,367例(39.4%)因疗效不佳/失效、不良事件、医生或患者决定停药,192例(20.6%)因疗效不佳/失效停药,102例(10.9%)因不良事件停药。
  • 校正倾向评分后,两组因任何原因停药无显著差异(HR 1.14,95%CI 0.90-1.46,p=0.28)。
  • 两组因疗效不佳/失效停药无显著差异(HR 1.01,95%CI 0.70-1.47,p=0.95),因不良事件停药无显著差异(HR 1.06,95%CI 0.64-1.73,p=0.83)。
  • 在生物制剂初治患者中亦得到相似结果。

临床怎么用

  • 临床选择TNFi或非TNFi生物制剂时,不应将疗效不佳/失效或不良事件停药风险作为区分依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Time to discontinuation of biologic therapy may be related to mechanism of action. We aimed to compare discontinuation of tumor necrosis factor inhibitors (TNFi) versus non-TNFi in an observational rheumatoid arthritis cohort. METHODS: Patients enrolled in the Ontario Best Practices Research Initiative (OBRI) starting biologic agents on or after 1st January 2010 were included. Time to discontinuation due to (1) any reason, (2) any of lack/loss of response, adverse events (AEs), physician, or patient decision, (3) lack/loss of response, and (4) AEs were assessed using Kaplan-Meier survival and Cox proportional hazards regression analysis. RESULTS: A total of 932 patients were included of whom 174 (18.7%) received non-TNFi and 758 (81.3%) received TNFi. Over a median follow-up of 1.7 years, discontinuation was reported for 416 (44.6%) due to any reason, 367 (39.4%) due to any of lack/loss of response, AEs, physician, or patient decision, 192 (20.6%) due to lack/loss of response, and 102 (10.9%) due to AEs. After adjusting for propensity score, there was no significant difference in discontinuation between the two classes due to any reason [HR 1.14 (0.90-1.46), p = 0.28], lack/loss of response [HR: 1.01 (0.70-1.47), p = 0.95], and AEs [HR: 1.06 (0.64-1.73), p = 0.83]. Similar results were found in biologic naïve patients. CONCLUSIONS: This analysis demonstrates that discontinuation of therapy is similar in patients started on TNFi and non-TNFi therapies. There was also no significant difference in stopping due to lack/loss of response or AEs, suggesting that these reasons should not drive the selection of one treatment over another.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Movahedi M, Hepworth E, Mirza R, et al. Discontinuation of biologic therapy due to lack/loss of response and adverse events is similar between TNFi and non-TNFi class: Results from a real-world rheumatoid arthritis cohort. Semin Arthritis Rheum. 2020. PMID: 32911288. doi:10.1016/j.semarthrit.2020.06.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。